Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Apomine, a novel 1,1 bisphosphonate ester, increases the rate of degradation of HMG-CoA reductase, inhibiting the mevalonate pathway and thereby blocking cholesterol biosynthesis. We have investigated whether Apomine can induce myeloma cell apoptosis in vitro and modulate myeloma disease in vivo. Ap...
Main Authors: | Edwards, C, Mueller, G, Roelofs, A, Chantry, A, Perry, M, Russell, R, Van Camp, B, Guyon-Gellin, Y, Niesor, E, Bentzen, C, Vanderkerken, K, Croucher, P |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2007
|
Registos relacionados
-
Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro
Por: Roelofs, A, et al.
Publicado em: (2005) -
APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
Por: Croucher, P, et al.
Publicado em: (2002) -
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Por: Roelofs, A, et al.
Publicado em: (2007) -
Novel insights into the anti-tumour mechanism of action of apomine and its synergistic interaction with lovastatin in myeloma cells in vitro
Por: Roelofs, A, et al.
Publicado em: (2006) -
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Por: Croucher, P, et al.
Publicado em: (2003)